SEC Form 4 · accession 0001213900-17-002644
ORAMED PHARMACEUTICALS INC. · ORMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald Edward Law
Officer — Chief Strategy Officer
Period of report
Mar 20, 2017
Accepted (ET)
Mar 21, 2017 · 12:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001176309
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $6.00 | Mar 20, 2017 | A | 37,152 | A | — | Mar 20, 2027 | Common Stock | 37,152 | 37,152 | D |
Explanation of responses
- F1The Stock Option shall vest in 24 consecutive equal monthly installments commencing March 31, 2017.